2019 novel coronavirus infection and gastrointestinal tract |
1 |
| 2019 Novel Coronavirus—Important Information |
2 |
| 2019_nCoVRapid classification of betacoronaviruses and identification of traditional |
3 |
| 2019-nCoV epidemic what about pregnancies |
4 |
| 2019-nCoV in context lessons learned |
5 |
| 2019-novel Coronavirus severe adult respiratory distress |
6 |
| 2019-novel-coronavirus--2019-nCoV--outbrea_2020_Journal-of-Global-Antimicrob |
7 |
| 2019-novel-coronavirus-disease--COVID-19--in-T_2020_Journal-of-Microbiology- |
8 |
| A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery |
9 |
| A conceptual model for the coronavirus disease 2019 (COVID-19) |
10 |
| A conceptual model for the outbreak of Coronavirus disease 2019 (COVID-19) in Wuhan, China with individual reactio-OCM_K8DT |
11 |
| A distinct name is needed for the new coronavirus |
12 |
| A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmissio-BXUMJ4IU |
13 |
| A Genomic Perspective on the Origin |
14 |
| A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan |
15 |
| A mild type of childhood Covid-19 - A case report |
16 |
| A new pandemic out of China the Wuhan 2019-nCoV coronavirus |
17 |
| A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome |
18 |
| A Novel Coronavirus Emerging in China Key Questions for Impact Assessment |
19 |
| A Novel Coronavirus from Patients with |
20 |
| A novel coronavirus outbreak of global health concern |
21 |
| A Novel Coronavirus(COVID-19) Outbreak A Call for Action |
22 |
| A novel presentation of COVID-19 via community acquired infection |
23 |
| A pneumonia outbreak associated with a new coronavirus of probable bat origin |
24 |
| A potential role for integrins in host cell entry by SARS-CoV-2 |
25 |
| A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19 The |
26 |
| A risk-based approach is best for decision making on holding mass gathering events |
27 |
| A segregated-team model to maintain cancer care during the COVID-19 outbreak at |
28 |
| A Sequence Homology and Bioinformatic Approach |
29 |
| A special case of COVID-19 with long duration of viral shedding for 49 days |
30 |
| A strategy to prevent future epidemics similar to the 2019-nCoV outbreak |
31 |
| A-case-of-COVID-19-and-pneumonia-returning-from-M_2020_Journal-of-Microbiolo |
32 |
| Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19) |
33 |
| Actualización de la situaciónepidemiológica de la infección porSARS-CoV-2 en Espa˜na. |
34 |
| ACUTE KIDNEY INJURY ASSOCIATED WITH |
35 |
| Adaptations de la prise en charge des patients en Nutrition Artificielle à Domicile au cours |
36 |
| Advance of promising target sagainst Q1 |
37 |
| Advice on Standardized Diagnosis and Treatment for Spinal Diseases during the Coronavirus Disease 2019 Pandemic |
38 |
| Aetiology of lower respiratory tract infection in adults in primary care a prospective study in 11 European countries |
39 |
| Africa prepares for coronavirus |
40 |
| Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome C-9AO8OJFO |
41 |
| Aminoquinolines against coronavirus disease 2019 (COVID-19) |
42 |
| An update on the 2019-nCoV outbreak |
43 |
| An updated estimation of the risk of transmission of the novel |
44 |
| Analysis and forecast of COVID-19 spreading in China, Italy and France |
45 |
| ANALYSIS Nearly every persondying from the coronavirus likely has these three things in common |
46 |
| Analysis of angiotensin-converting enzyme 2 (ACE2) from |
47 |
| Analysis of preferred codon usage in the coronavirus N genes and their |
48 |
| Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by |
49 |
| And now for something completely different from |
50 |
| Anesthetic Management of Patients Undergoing Aortic Dissection Repair With Suspected Severe Acute Respiratory Synd-63KLPUJD |
51 |
| Anesthetic-Management-of-Patients-with-COVID-_2020_Journal-of-Cardiothoracic |
52 |
| Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor molecular mechanisms and potential therapeutic target |
53 |
| Another coronavirus, another epidemic, another warning |
54 |
| Antigenic variation among recent Japanese isolates of bovine |
55 |
| Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |
56 |
| Antipsoriatic treatments covid 19 |
57 |
| Application of the ARIMA model on the COVID- |
58 |
| Applying lessons from SARS to a newly identifi ed coronavirus |
59 |
| Approaches to the management of patients in oral and maxillofacial surgery during |
60 |
| Arbidol combined with LPVr versus LPVr alone against Corona Virus Disease 2019 A retrospective cohort study |
61 |
| Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection |
62 |
| A-review-of-the-2019-Novel-Coronavirus--COVI_2020_International-Journal-of-A |
63 |
| Arguments in favour of remdesivir for treating SARS-CoV-2 infections |
64 |
| Arthralgia as an initial presentation of COVID‑19- observation |
65 |
| Assessment of the SARS-CoV-2 basic |
66 |
| Association between ambient temperature and COVID-19 |
67 |
| Assurer les soins aux patients souffrant de troubles psychiques en |
68 |
| Asymptomatic novel coronavirus pneumonia patient outside Wuhan |
69 |
| Asymptomatic-carrier-state--acute-respiratory-disease-_2020_Journal-of-Micro |
70 |
| Asymptomatic-coronavirus-infection--MERS-CoV-a_2020_Travel-Medicine-and-Infe |
71 |
| A-systematic-review-on-the-efficacy-and-safety-of-chloro_2020_Journal-of-Cri |
72 |
| b68 Consecutive patients assessed for COVID-19 infection; experience from a UK regional infectious disease unit |
73 |
| Baricitinib for COVID-19- a suitable treatment |
74 |
| Base protocol for real time active random surveillance of |
75 |
| Breakthrough, Chloroquine phosphate has shown apparent |
76 |
| Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses |
77 |
| Building resilience against biological hazards and pandemics COVID-19 and |
78 |
| C0031_Specialty-guide_LD-and-coronavirus-v1_-24-March (1) |
79 |
| C0032-Maintenance-of-TB-services_26-March-FINAL (1) |
80 |
| C033-Specialty-guide_-Stroke-and-coronavirus-v1-24March_ (1) |
81 |
| C0063-Specialty-guide-_Respiratory-and-Coronavirus-_v1_26-March (1) |
82 |
| C0081-Speciality-guide-Palliative-care-and-coronavirus (1) |
83 |
| C0086_Specialty-guide-_Fragility-Fractures-and-Coronavirus-v1-26-March (1) |
84 |
| C0086_Specialty-guide_-Paediatric-critical-care-v1-26-March (1) |
85 |
| C0087-specialty-guide-critical-care-standard-operating-procedure-and-coronavirus-v1-28-march |
86 |
| C0099-specialty-guide-immunoglobulin-coronavirus-v1-31-march (1) |
87 |
| Can Bioactive Lipids Inactivate Coronavirus (COVID-19) |
88 |
| Can we contain the COVID-19 outbreak with the same measures as for SARS |
89 |
| Canada needs to rapidly escalate public health interventions for its COVID-19 |
90 |
| Cancer patients in SARS-CoV-2 infection a nationwide |
91 |
| Canwe contain the COVID-19 outbreak with the same |
92 |
| Cardiac troponin I in patients with coronavirus |
93 |
| Cardiovascular disease and COVID-19 |
94 |
| Cardiovascular-Considerations-for-Patients--Health-Ca_2020_Journal-of-the-Am |
95 |
| Caring for persons in detention suffering with mental illness during the |
96 |
| CARTA CIENTÍFICAPrimer caso de infección neonatalpor SARS-CoV-2 |
97 |
| Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Develop-9IS26O1D |
98 |
| Case of the Index Patient Who Caused |
99 |
| Caution and clarity required in the use of chloroquine for COVID-19 |
100 |
| CDC Director Says 1 In 4 May Have No Coronavirus Symptoms _ Shots - Health News |
101 |
| CD-sACE2 inclusion compound An effective treatment for corona virus disease 2019 COVID |
102 |
| Challenges and countermeasures for organ |
103 |
| Challenges of coronavirus disease 2019 |
104 |
| Challenges-of-SARS-CoV-2-and-lessons-learnt-from-SARS_2020_Journal-of-Clinic |
105 |
| Characteristics of and Important Lessons From |
106 |
| Characteristics of COVID-19 infection in Beijing |
107 |
| Characterization of novel monoclonal antibodies against MERS- |
108 |
| Chest CT for Non-Radiologists- A Practical Guide-2018 |
109 |
| Chest CT for Typical 2019-nCoV Pneumonia Relationship to Negative RT-PCR |
110 |
| China coronavirus cases surge as official admits |
111 |
| China coronavirus Hong Kong health staff strike to |
112 |
| China coronavirus mild but infectious cases may make |
113 |
| China coronavirus partial border closures into Hong |
114 |
| China coronavirus should be on “everybody’s agenda,” |
115 |
| China coronavirus what do we know so far |
116 |
| China coronavirus WHO declares international |
117 |
| China empowers Internet hospital to fight against COVID-19 |
118 |
| Chinese experts’ consensus on the Internet of Things-aided diagnosis and |
119 |
| Chinese Health Care Workers and COVID-19 For Whom the Bell Tolls |
120 |
| Chinese premier rallies medics in coronavirus fight |
121 |
| Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 |
122 |
| Chloroquine and hydroxychloroquine as available weapons to fight |
123 |
| Chloroquine-and-hydroxychloroquine-in-the-treatment-of-_2020_Diabetes---Meta |
124 |
| Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID‑19) infection |
125 |
| Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 |
126 |
| CIENTÍFICAPrimer caso de infección neonatalpor SARS-CoV-2 en Espa˜na |
127 |
| CLEARED_Specialty-guide_-NIV-respiratory-support-and-coronavirus-v2-26-March-003 (1) |
128 |
| Clinical and CT features in pediatric patients with COVID-19 infection, Different points from adults |
129 |
| Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19) |
130 |
| Clinical and CT imaging features of the COVID-19 pneumonia Focus |
131 |
| Clinical and epidemiological features of 36 children with |
132 |
| Clinical and High-Resolution CT Features of the COVID-19 Infection, Comparison of the Initial and Follow-up Changes |
133 |
| Clinical and virological data of the first cases of COVID-19 |
134 |
| Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19)A multi-center-R2_O8L7J |
135 |
| Clinical characteristics and intrauterine vertical transmission |
136 |
| Clinical characteristics and therapeutic procedure for four cases |
137 |
| Clinical Characteristics of 138 Hospitalized Patients |
138 |
| Clinical Characteristics of Coronavirus |
139 |
| Clinical characteristics of COVID-19-infected cancer patients A retrospective case |
140 |
| Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province A Multicenter Descriptive Study |
141 |
| Clinical characteristics of laboratory confirmed positive cases of SARS-CoV- |
142 |
| clinical characteristics of medical staff in covid 19 |
143 |
| Clinical characteristics of novel coronavirus |
144 |
| Clinical considerations for patients with diabetes in times of COVID-19 |
145 |
| Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China a single-centere-R6XSVQPJ |
146 |
| Clinical course and risk factors for mortality of adult |
147 |
| Clinical evidence does not support corticosteroid treatment |
148 |
| Clinical features and obstetric and neonatal outcomes |
149 |
| Clinical features and short-term outcomes |
150 |
| Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus -AOEO83FO |
151 |
| Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection |
152 |
| Clinical features of COVID-19 in elderly patients A comparison with young and middle-aged patients |
153 |
| Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China |
154 |
| Clinical findings in a group of patients infected with the 2019 |
155 |
| Clinical guide for the management of major trauma patients during the coronavirus pandemic |
156 |
| Clinical Overview_Coronavirus novel coronavirus (COVID-19) |
157 |
| Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China |
158 |
| Clinical progression of patients with COVID-19 in Shanghai, China |
159 |
| Clinical Study of Mesenchymal Stem Cell Treatment for Acute |
160 |
| Clinical trial analysis of 2019-nCoV therapy |
161 |
| Clinical, laboratory and imaging features of COVID-19 A systematic review |
162 |
| Clinical-and-computed-tomographic-imaging-features-of-novel_2020_Journal-of- |
163 |
| Clinical-characteristics-of-severe-acute-respiratory-syndr_2020_Journal-of-I |
164 |
| Clinical-features-of-cases-and-a-cluster-of-Coronaviru_2020_Travel-Medicine- |
165 |
| clinical-guide-for-staff-supporting-patients-with-a-learning-disability-autism-or-both-easy-read |
166 |
| clinical-guide-rheumatology-patients-v1-19-march-2020-updated (1) |
167 |
| clinical-management-of-persons-admitted-to-hospita-v1-19-march-2020 |
168 |
| CO0043_Specialty-guide-and-coronavirus_-MSK-corcosteroid_-v1-25March (1) |
169 |
| Combination of RT-qPCR Tes t ing and Clinical Features For |
170 |
| Commentary Of chloroquine and COVID-19 |
171 |
| Comments on P¨ reliminary estimation of the basic reproduction number of novel Coronavirus |
172 |
| Community pharmacist in public health emergencies Quick to action |
173 |
| Community pharmacists and communication in the time of COVID-19 |
174 |
| Comparison of different samples for 2019 novel coronavirus |
175 |
| Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome |
176 |
| Comparison-of-clinical-characteristics-of-coronavirus-di_2020_Travel-Medicin |
177 |
| Composition-of-human-specific-slow-codons-and-slow-di-co_2020_Journal-of-Mic |
178 |
| Computers-and-viral-diseases--Preliminary-bioinformatics-stud_2020_Computers |
179 |
| Considerations in performing endoscopy during the COVID-19 pandemic |
180 |
| Contentious issues and evolving concepts in the clinical presentation |
181 |
| Continuous evolution of avian infectious bronchitis virus resulting in different variants co-circulating in southern China |
182 |
| Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 |
183 |
| Corona Virus Disease 2019, a growing threat to children |
184 |
| Corona Virus International Public Health Emergencies Implications for Radiology Management |
185 |
| corona virus |
186 |
| Coronavirus (COVID-19) Outbreak What the Department of Radiology Should Know |
187 |
| Coronavirus 2019-nCoV Is the genie already out of the bottle |
188 |
| Coronavirus can infect cats — dogs, not so much |
189 |
| Coronavirus Disease (COVID-19) Spectrum of CT Findings and Temporal Progression of the Disease |
190 |
| Coronavirus disease 2019 (COVID-19)- facts and controversies |
191 |
| Coronavirus Disease 2019 (COVID-19) Pneumonia |
192 |
| Coronavirus Disease 2019 (COVID-19), A Perspective from China |
193 |
| Coronavirus disease 2019 (COVID-19) |
194 |
| Coronavirus Disease 2019 and Influenza |
195 |
| Coronavirus Disease COVID-19, A New Threat to Public Health |
196 |
| Coronavirus doctor who faced backlash from police |
197 |
| Coronavirus does spread through the air and lingers in rooms long after patients have left |
198 |
| Coronavirus global stocks of protective gear are |
199 |
| Coronavirus in mother and baby |
200 |
| Coronavirus infections reported by ProMED, February 2000–January 2020 |
201 |
| Coronavirus latest pandemic could have killed 40 million without any action |
202 |
| Coronavirus masks advice could change after new evidence emerges |
203 |
| Coronavirus online GP bookings should be stopped |
204 |
| Coronavirus- Potential vaccine generates enough antibodies to fight off virus, first peer-reviewed study suggests |
205 |
| Coronavirus- Scientists in Australia begin testing two potential vaccines |
206 |
| Coronavirus shows how UK must act quickly before |
207 |
| Coronavirus UK screens direct flights from Wuhan |
208 |
| Coronavirus-2019-nCoV--A-brief-perspective-from-the-f_2020_Journal-of-Infect |
209 |
| Coronavirus-Disease-2019--Coronaviruses-and-Blo_2020_Transfusion-Medicine-Re |
210 |
| Coronavirus-Disease-2019--COVID-19--and-Pregna_2020_American-Journal-of-Obst |
211 |
| Coronavirus-disease-2019--COVID-19---current_2020_International-Journal-of-A |
212 |
| Coronavirus-Disease-2019--COVID-19--Pand_2020_American-Journal-of-Obstetrics |
213 |
| Coronavirus-Disease--COVID-19---A-primer-fo_2020_The-American-Journal-of-Eme |
214 |
| Coronaviruses in animals and humans |
215 |
| Coronaviruses |
216 |
| Covid 19 epidemic disease Characteritics in children |
217 |
| COVID 19 in INDIA Strategies to combat from |
218 |
| COVID-19 - Face Masks and Human-to-human Transmission |
219 |
| Covid-19 — Navigating the Uncharted |
220 |
| COVID-19 – the role of mass gatherings |
221 |
| COVID-19 A critical care perspective informed by lessons learnt from |
222 |
| COVID-19 a novel coronavirus and a novel |
223 |
| Covid-19 a puzzle with many missing pieces |
224 |
| COVID-19 and Blood Safety Help with a Dilemma |
225 |
| COVID-19 and diabetes Can DPP4 inhibition play a |
226 |
| COVID-19 and ImmunomodulatorImmunosuppressant Use in Dermatology |
227 |
| COVID-19 and Italy what next |
228 |
| COVID-19 and the anti-lessons of history |
229 |
| Covid-19- BSTIBSGAR decision tool for chest imaging in patients undergoing CT for acute surgical abdomen |
230 |
| COVID-19 Challenges to GIS with Big Data |
231 |
| COVID-19- combining antiviral and anti-inflammatory treatments |
232 |
| COVID-19 Computed Tomography Findings A Systematic Review and Meta-Analysis |
233 |
| COVID-19 consider cytokine storm syndromes and immunosuppression |
234 |
| COVID-19 Gastrointestinal Manifestations and Potential Fecal–Oral Transmission |
235 |
| COVID-19 Global radiation oncology’s targeted response for pandemic |
236 |
| COVID-19 HOW CAN A DEPARTMENT OF GENERAL SURGERY SURVIVE TO A |
237 |
| COVID-19 in children More than meets the eye |
238 |
| COVID-19 in children the link in the transmission chain |
239 |
| COVID-19 in Hemodialysis Patients A Report of 5 Cases |
240 |
| COVID-19 in Kidney Transplant Recipients |
241 |
| COVID-19 in Latin America The implications of the first confirmed case in Brazil |
242 |
| COVID-19 in patients with cardiovascular |
243 |
| COVID-19 in Singapore—Current Experience |
244 |
| COVID-19 Infection in a Patient with End-Stage Kidney Disease |
245 |
| COVID-19 Lessons from SARS and MERS |
246 |
| COVID-19 Melatonin as a Potential Adjuvant Treatment |
247 |
| COVID-19 Pandemic Staged Management of Surgical Services for Gynecology and |
248 |
| COVID-19 Personal Protective Equipment (PPE) for the emergency |
249 |
| COVID-19 pneumonia what has CT taught us |
250 |
| Covid-19 preparedness, decentralisation, and the hunt |
251 |
| COVID-19 preparing for superspreader potential among Umrah pilgrims to Saudi Arabia |
252 |
| Covid-19 school closures and bans on mass |
253 |
| COVID-19 spike-host cell receptor GRP78 binding site prediction |
254 |
| Covid-19 surge in cases in Italy and South Korea |
255 |
| COVID-19 therapeutic options for patients with Kidney Disease |
256 |
| COVID-19 through the lens of gerontology |
257 |
| Covid-19 Trump says risk to Americans is “very low” |
258 |
| COVID-19 Yet another coronavirus challenge in |
259 |
| COVID-19 Zoonotic aspects |
260 |
| COVID–19, Journal de bord–18022020– |
261 |
| COVID-19, the gendered impacts of the outbreak |
262 |
| COVID-19, una emergencia de salud pública mundial |
263 |
| COVID-19__lung_cancer_pathway_guidance_final |
264 |
| COVID-19--Epidemiology--Evolution--and-Cross-Disci_2020_Trends-in-Molecular- |
265 |
| COVID-19-infection-and-rheumatoid-arthritis--Faraway--_2020_Autoimmunity-Rev |
266 |
| COVID-19-infection--Origin--transmission--and-charact_2020_Journal-of-Advanc |
267 |
| COVID-19—New Insights on a Rapidly Changing Epidemic |
268 |
| COVID-19--SARS-and-MERS--are-they-closely-_2020_Clinical-Microbiology-and-In |
269 |
| covid-19-testing-and-staff-retention-letter-29-march-2020 (1) |
270 |
| COVID-2019 the role of the nsp2 and nsp3 in its pathogenesis |
271 |
| Critical care crisis and some |
272 |
| Critical care management of adults |
273 |
| Current knowledge about the antivirals remdesivir (GS-5734) and GS- |
274 |
| Defining the Epidemiology of Covid-19 — Studies Needed |
275 |
| Dental journals and coronavirus disease (COVID-19) A current view |
276 |
| Dermatirtis and Covid 19 |
277 |
| Detection of SARS-CoV-2 in Different Types of Clinical Specimens |
278 |
| Developing antibody tests for SARS-CoV-2 |
279 |
| Developing Covid-19 Vaccines at Pandemic Speed |
280 |
| Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis |
281 |
| Development of epitope-based peptide vaccine against novel |
282 |
| Development of protection against coronavirus induced diseases. A review |
283 |
| Diabetes is a risk factor for the progression and prognosis of COVID-19 |
284 |
| Diagnosis of SARS-CoV-2 Infection based on CT scan vs. RT-PCR, Reflecting on Experience from MERS-CoV |
285 |
| Diagnosis of severe respiratory infections |
286 |
| Diagnosis of the Coronavirus disease (COVID-19) rRT-PCR or CT |
287 |
| Diagnostic-value-and-dynamic-variance-of-serum_2020_International-Journal-of |
288 |
| DisinfectionChamber finalized |
289 |
| Do children need a longer time to shed SARS- |
290 |
| Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection |
291 |
| Duration of quarantine in hospitalized patients with severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) i-2GFNCU3W |
292 |
| Duration of serum neutralizing antibodies for |
293 |
| Duration-of-quarantine-in-hospitalized-patients-with-severe_2020_Journal-of- |
294 |
| Dynamic-change-process-of-target-genes-by-RT-PCR-testing-of-S_2020_Clinica-C |
295 |
| Early epidemiological analysis of the coronavirus disease |
296 |
| Early Transmission Dynamics in Wuhan, China, |
297 |
| Early-dynamics-of-transmission-and-control-of-COVID-_2020_The-Lancet-Infecti |
298 |
| EASL-ESCMID-Position-Paper-on-COVID-19-and-the-liver-2-April-2020 |
299 |
| Economic Impacts of Wuhan 2019-nCoV on China and the |
300 |
.JPG)
